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Abstract 
Background: Prolactin (PRL) has been implicated in the development of different types of cancer. However, signal‑
ing pathways might be activated depending on various forms of prolactin receptor (PRLR). JAK/STAT is an important 
pathway associated with PRL effects. The activation of JAK/STAT pathway might activate antiapoptotic genes that 
could importantly lead to progression of tumorigenesis. Recently, we have reported that PRL is associated with cell 
survival by inhibition of apoptosis and the precise activated signaling pathways for this process are still questioned. 
The purpose of this study was to evaluate the activation of different signaling pathways in response to PRL as well as 
to identify the induction of antiapoptotic genes.
Methods: Cervical cancer cell lines HeLa, SiHa and C‑33 A were stimulated with PRL (200 ng/mL) for 30 and 60 min 
and non stimulated cells were used to measure basal protein expression. Inhibition assays were performed by using 
Jak2 specific inhibitor AG490, either alone or in combination with PRL for 48 h. Western blot were carried out to evalu‑
ate protein induction of the different signaling pathways and antiapoptotic proteins. Significant effects were deter‑
mined by using ANOVA test.
Results: STAT3 was significantly activated in cervical cancer lines in comparison with non‑tumorigenic keratinocytes 
HaCaT. No significant differences were found when analyzing MAPK and PI3K signaling pathways. An increase of antia‑
poptotic genes Bcl‑xl, Bcl‑2, survivin and Mcl‑1 was observed after stimulus with PRL; however, after inhibition with 
AG490, the induction of antiapoptotic genes was decreased.
Conclusion: Our data suggests that STAT3 is an important signaling pathway activated by PRL in cervical cancer 
cells and it modulates the induction of antiapoptotic genes. Blocking STAT3 could represent a possible therapeutic 
strategy in cervical cancer.
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Background
Prolactin (PRL) is a peptidic hormone with diverse 
biological effects such as cell proliferation, immu-
noregulation, osmoregulation and reproduction. PRL 
is synthesized mainly by the pituitary gland. However, 
other cell types have the capacity to produce PRL in an 
autocrine-paracrine manner acting as a growth factor, 
neurotransmitter and inmunomodulator [1]. These func-
tions are the result of PRL binding to prolactin receptor 
(PRLR) activating the signaling pathways Janus kinase/
Signal transducer and activator of transcription (JAK/
STAT), Mitogen-activated protein kinases (MAPK) 
and phosphoinositide 3 kinase (PI3K). Several forms 
of PRLR have been described including a long form, an 
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intermediate form and two short forms, each of them 
with the ability to activate different signaling pathways 
[2–4].
It has been documented that the activated signaling 
by PRL/PRLR is associated with tumor development. 
The association of PRL and its receptor with tumor pro-
gression was first established on animal models many 
decades ago [5]. Recently, there are several studies that 
involve PRL in the development of different types of can-
cer such as breast [6–8], prostate [9, 10], ovarian [11] and 
cervical [12, 13].
With regard to cervical cancer we reported an overex-
pression of PRLR and the presence of different forms in 
tissues derived from cervical cancer in comparison with 
premalignant lesions and healthy tissues [12]. This accu-
mulation in the cytoplasm could be due to alterations 
in PRLR leading to a decrease of PRLR phosphorylation 
and subsequent lack of ubiquitination which is associ-
ated with the non-degradative process and as a result, the 
accumulation of PRLR [14]. In addition, we reported that 
PRL and PRLR induction is associated with cell survival, 
mainly by inhibition of apoptosis, but not by inducing 
proliferation, in cervical cancer cell lines [15].
It has been documented that the activation of these 
signaling pathways induces the induction of target genes 
associated with proliferation and antiapoptotic effects in 
breast cancer [16]. However, there are no investigations 
focused on the induction of antiapoptotic genes in cervi-
cal cancer in response to PRL/PRLR.
For this reason, the purpose of this study was to evalu-
ate the signaling pathways involved in the antiapoptotic 
effect mediated by PRL/PRLR in cervical cancer, as well 
as the induction of antiapoptotic genes that could be sub-
serving the development of the carcinogenic process.
Materials and methods
Reagents
Prolactin (L-4021) was obtained from Sigma-Aldrich®. 
Polyvinylidenedifluoride (PVDF) membranes, enhanced 
chemi-luminiscence (ECL), Western blotting detection 
kit (WBKLS0500), and monoclonal antibody anti-actin 
(Clone C4) were purchased from Merck Millipore® (EMD 
Millipore Corporation Billerica, MA, USA). Polyclonal 
antibodies anti-pSTAT3 (Ser 727) sc-13564, anti-STAT3 
(H-190) sc-7179, anti-pERK 1/2 (Thr 202) sc-101760, 
anti-pAKT 1/2/3 (ser 473) sc-101629, anti-AKT 1/2/3 
(H-136) sc-8312 as well as the monoclonal antibodies 
anti-ERK2 (H-9) sc-271451, anti-bcl-xl (H-5) sc-8392 and 
anti-bcl-2 (C-2) sc-7382 were obtained from Santa Cruz 
Biotechnology®, inc (Santa Cruz, CA). Phospho-p38 (Thr 
180/Tyr 182) (D3F9) #4511 and p38 MAPK #9212 were 
purchased from Cell Signaling Technology® (Danvers, 
MA, USA). Polyclonal antibody anti-survivin AF886 was 
purchased from R&D Systems® (R&D Systems, inc. Min-
neapolis, Mn). Inhibitor for JAK/STAT signaling pathway 
α-cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG490) 
was dissolved in dimethyl sulfoxide (DMSO) and stored 
at −20  °C as recommended by the manufacturer. RPMI 
1640, DMEM and Fetal Bovine Serum (FBS) were pur-
chased from Gibco®, Life technologies (Carlsbad, CA).
Cell culture
Cervical cancer derived cells (HeLa, SiHa, C-33A), as 
well as breast cancer derived cells overexpressing PRLR 
(MCF-7, T-47D), and non-tumorigenic immortalized 
keratinocytes (HaCaT) from American Type Culture Col-
lection® (University Boulevard Manassas, VA) were used. 
All cells were grown with RPMI 1640 or DMEM medium 
supplemented with 5  % of Fetal Bovine Serum (FBS), 
penicillin G, streptomycin and amphotericin B. Media, 
FBS, antibiotic and antimicotic were obtained from 
Gibco®, Life technologies (Carlsbad, CA).
Cells were cultured in a jacket-water incubator at 37 °C 
with an atmosphere of 5 % CO2. All cells were grown to 
reach 80 % confluence so they were used for assays.
The investigation was approved by the ethical investiga-
tion and biosecurity committee of the University Center 
of Health Sciences at the University of Guadalajara (Ref-
erence Number C.I. 093/13 CUCS).
Prolactin stimuli and protein extraction
Cells were seeded in 6-well plates and stimulated with 
600  ng of PRL for either 30 or 60  min. Proteins were 
extracted by using 100 μL RIPA buffer (50  mM Tris, 
100  mM NaCl, 1  % NP40, 0.5  % sodiym deoxycolate 
and 0.1 % sulfate dodecilsulphate (SDS) in addition of a 
cocktail of protease inhibitors (pepstatin A, aprotinin A, 
chymostatin, antipain, bestatin and PSMF) as well as a 
phosphatase inhibitor (Na3VO4) followed by centrifiga-
tion at 4  °C for 15  min. Protein extract concentrations 
were determined by using Lowry method (DC Protein 
Assay, BioRad Laboratories, Hercules, CA).
Western blot
Fifty micrograms of total protein extract were mixed with 
loading buffer and denatured at 95  °C for 5  min. After-
wards they were loaded on 10  % SDS polyacrylamide 
gels to be resolved. Electrotransference was carried out 
in polyvinylidene difluoride membranes (BioRad Labo-
ratories, Hercules, CA). Blocking solution was prepared 
with 5  % of Blotting Grade Blocker (BioRad Laborato-
ries, Hercules, CA) and membranes were incubated in 
this solution for 2  h. Solutions with primary antibodies 
were prepared at a dilution of 1:500 and 1:10,000—in the 
case of β-actin—and membranes were kept overnight 
followed by either anti-mouse or anti-rabbit secondary 
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antibody solutions (diluted 1:5000). Reveal process was 
developed with a chemiluminiscence system (Immo-
bilion, Merck Millipore®). Microchemi 4.2 was used to 
reveal membranes and measure optical density as well.
STAT3 inhibition assay
Cells were seeded in six-well plates for 48 h under three 
conditions: no stimulus, PRL stimulus, and PRL stimulus 
plus AG490 inhibitor. During the time of stimuli, cells 
were kept at 37 °C and 5 % CO2. Once the time of stimuli 
was over, proteins were extracted as described above.
Apoptotic assay (TUNEL assay)
To carry out TUNEL assay we used the kit APO-BrdU 
(Invitrogen). Cells were grown for 24  h in eight-well 
chamber slides seeded with 5 ×  104 cells per well were 
treated with etoposide alone or in combination with PRL 
or PRL plus AG490 for 24 h and incubated at 37 °C. The 
slides were washed with PBS and fixed with 4  % para-
formaldehyide for 30  min at room temperature. Fixed 
cells were washed and permeabilized by using 0.2  % 
Tween 20 for 10  min and then incubated with terminal 
deoxynucleotidyl transferase and Brd-U for 1 h at 37 °C. 
After rinsing with PBS, cells were treated with Alexa 
Fluor 488 dye-labeled anti BrdU antibody at 37  °C for 
30  min and mounted with a glass coverslip. Staining of 
DNA fragmentation was observed with ultraviolet fluo-
rescent microscope (Carl Zeiss) counting at least 200 
cells per well.
Statistical analysis
Data was analyzed by using Graph pad Prism software 
(Graph pad version 6.01). Significant effects were deter-
mined using ANOVA. Statistically significant differences 
were considered for p values <0.05.
Results
To determine the effect of PRL on the activation of dif-
ferent signaling pathways in the uterine cervical cancer 
cell line compared to non-tumorigenic immortalized 
keratinocytes HaCaT, all cell lines were stimulated with 
PRL during 30 and 60 min. The MCF-7 and T-47D breast 
cancer cell lines overexpressing PRLR were used. Immu-
noblotting analysis of cellular proteins was performed to 
assess the induction of pS727-STAT3, STAT3, pT202-
ERK, ERK, pT180/pY182-p38, p38, pS473-Akt and Akt.
Prolactin induces STAT3 phosphorylation in cervical cell 
lines
The results showed a differential expression pattern 
of constitutively active pS727-STAT3 among the ana-
lyzed cell lines. In comparison to the HPV-negative 
C-33 A cells, SiHa and HeLa cells demonstrated a higher 
pS727-STAT3 basal expression. However, treatment with 
PRL increased pS727-STAT3 induction in HeLa and 
C-33 A. In MCF-7 and T-47D, increased induction of 
pS727-STAT3 by the effect of PRL was also observed. In 
contrast, no differences at 30 min and a decreased pS727-
STAT3 expression at 60 min in the HaCaT cell line were 
observed (Fig. 1).
Prolactin increases phosphorylation of Akt in the T‑47D cell 
line and decreases in the C‑33 A cell line
The expression of pS473-Akt was only observed in T-47D 
and C-33 A cell lines. PRL induced activation of Akt in 
T-47D and the opposite effect was observed in C-33 A 
(Fig. 2).
Prolactin modulates the phosphorylation of ERK and p38 
in cervical and breast cancer cell lines
The pT202-ERK expression was observed in cell lines 
T-47D, HeLa, SiHa, C-33 A and HaCaT. PRL stimulus 
induced a significant increase in the phosphorylation 
of ERK in T-47D, both at 30 and 60  min; on the other 
hand, a downregulation of pT202-ERK induction by 
PRL was observed in HeLa in a time-dependent manner 
and in C33 A at 60 min (Fig. 3a). Moreover, a significant 
increase of phospho-p38 induction modulated by PRL 
was perceived in cell lines MCF-7, C-33 A, HeLa, SiHa 
and HaCaT. The peak of p38 activation in MCF-7 and 
HeLa was observed at 30 min, while in cell lines C-33 A, 
SiHa and HaCaT, it was at 60 min (Fig. 3b).
The activation of STAT3 is directly correlated to the 
induction of anti‑apoptotic genes
STAT3 induction in cervical cancer cell lines was the 
only pathway that showed activation after PRL stimulus 
compared to HaCaT. Therefore, to test the functional 
relevance of active STAT3 in the induction of antiapop-
totic genes, we inhibited the JAK/STAT pathway by using 
AG490 inhibitor. In order to evaluate effectively that 
the signaling pathway had been inhibited, the induction 
of pS727-STAT3 was assessed. The results showed that 
the increment in the PRL-mediated phosphorylation 
of STAT3 in the cell lines HeLa, SiHa and C-33 A was 
detectable 48  h after treatment and that co-stimulation 
with the AG490 reduced this effect in the three cervical 
cancer cell lines (Fig. 4a).
After stimulation with PRL, an increment in the level 
of Bcl-xl was observed in HeLa, SiHa and C-33 A and 
the inhibition of STAT3 diminished the induction of this 
anti-apoptotic molecule in all three analyzed cell lines 
(Fig. 4b).
On the other hand, the induction of Bcl-2 was 
increased in C-33 A after treatment with PRL, and inhi-
bition of STAT3 reduced the induction in both HeLa and 
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C-33 A cell lines. In the SiHa cell line, the induction of 
Bcl-2 was not observed. The induction of survivin was 
increased in the cell lines HeLa and C-33 A after stimulus 
with PRL and the inhibition of STAT3 reduced its induc-
tion in all three analyzed cell lines (Fig. 4b).
When analyzing Mcl-1 expression we can observe that 
there is a decrease in its induction when blocking STAT3 
signalling in this 3 cell lines (Fig. 4b).
Apoptosis is directly related to decrease of antiapoptotic 
genes in HeLa cells
After stimuli with etoposide apoptosis is augmented in 
comparison to those non stimulated but this increase 
is diminished when PRL is present in the medium. Yet, 
after blocking JAK/STAT pathway apoptosis is restab-
lished (Fig. 4c).
Discussion
The abnormal induction of PRL/PRLR has been associ-
ated with the development and progression of various 
types of cancers such as breast [17], prostate [18, 19], 
colorectal [20, 21], larynx [22], and hepatocellular [23, 
24]. However, few studies have reported the induction 
of PRL/PRLR in cervical cancer, so their role has been 
poorly studied. A previous study reported that the pres-
ence of PRL is increased in cervical cancer tissue from 
patients compared with controls [25]. Additionally, an 
increase in serum PRL levels was reported in a consid-
erable number of patients with cervical cancer [26]. 
Recently, our research group observed a high induction 
of PRLR in samples of patients with cervical cancer com-
pared with samples from patients with intraepithelial 
lesions [12].
Fig. 1 Prolactin induces STAT3 phosphorylation in cervical cancer cell lines by western blot. a HeLa, SiHa and C‑33 A. Overexpressing PRLR breast 
cancer cell lines: MCF‑7 and T‑47D. Non‑tumorigenic immortalized keratinocytes: HaCaT. All the cells were treated under three conditions: no 
stimulus, 30‑min stimulus and 60‑min stimulus with PRL (200 ng/mL). b Induction of pS727‑STAT3 by western blot, comparisons were made versus 
non‑stimulated cells, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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Cancer development related to PRL, is mainly described 
in breast cancer [27, 28]. Some authors have reported that 
PRL promotes the proliferation of T-47D and MCF-7 cell 
lines [29]. In contrast, other authors show that PRL does 
not have any effect on cell proliferation in the breast can-
cer cell lines MDA-MB-231, T-47D, MCF-7 and Hs578T 
[8]. These differences may be caused by the use of differ-
ent techniques and culture conditions as well as differ-
ent clones for each cell line. Another study, reported that 
treatment with PRL does not promote proliferation in PC3 
and LNCaP cell lines derived from prostate cancer, but has 
shown a pro-apoptotic effect on the LNCaP cell line which 
responds to stimulation with androgens [30]. On the other 
hand, it has been reported that PRL stimuli prevents apop-
tosis after treatment with C2-ceramide in the breast can-
cer cell lines T-47D, MCF-7 and Hs578T [8].
Similar results, reported by our research group show 
that treatment with PRL has a protective effect against 
etoposide-induced apoptosis by decreasing the number 
of apoptotic cells in HeLa, SiHa y C33A, compared with 
the immortal human keratinocyte HaCaT cell line. This 
suggests that PRL plays an important role in the survival 
of cervical cell lines [15].
Regarding the activation of signaling pathways that 
modulate such effects, it has been reported that Jak2 is 
essential for the proliferative effects of PRL on the induc-
tion of breast tumorigenesis, however, deletion of Jak2 
after neoplastic transformation, does not have an impact 
on survival and proliferation of breast cancer cells in cul-
ture or in vivo [6].
In the same context, PRL/PRLR signaling has the abil-
ity to promote progression and invasion in breast cancer 
through independent pathways to JAK2/STAT5, such as 
c-Src, FAK and MAPK. In addition, PRL may promote 
cell motility and confer resistance to chemotherapy, 
which contributes to metastasis [28, 31].
In this study, at first instance, we analyzed which sign-
aling pathway is activated on cervical cancer cell lines 
after the stimulation with PRL; we observed an impor-
tant increase in STAT3 phosphorylation, compared to 
the HaCaT cell line; however, no changes were observed 
in the activation of other signaling pathways.
Previously, and consistent with our results, it has been 
reported that the signaling pathway that involves STAT3 
is activated constitutively in cervical cancer, this was 
observed in  vivo on the tissue from patients as well as 
Fig. 2 Effect of PRL treatment on AKT phosphorylation in cervical cancer cell lines by western blot. a HeLa, SiHa and C‑33 A. Overexpressing PRLR 
breast cancer cell lines: MCF‑7 and T‑47D. Non‑tumorigenic immortalized keratinocytes: HaCaT. All the cells were treated under three conditions: 
no stimulus, 30‑min stimulus and 60‑min stimulus with PRL (200 ng/mL). b Induction of pS473‑Akt by western blot, comparisons were made versus 
non‑stimulated cells, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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Fig. 3 Effect of PRL on MAPK phosphorylation in cervical cancer cell lines by western blot. a HeLa, SiHa and C‑33 A. Overexpressing PRLR breast 
cancer cell lines: MCF‑7 and T‑47D. Non‑tumorigenic immortalized keratinocytes: HaCaT. All the cells were treated under three conditions: no stimu‑
lus, 30‑min stimulus and 60‑min stimulus with PRL (200 ng/mL). b Induction of pT202‑ERK and pT180/pY182‑p38 by western blot, comparisons 
were made versus non‑stimulated cells, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 4 Effect of PRL and AG490 on bcl‑xl, bcl‑2, survivin and Mcl‑1 induction in cervical cancer cells. HeLa, SiHa and C‑33 A were treated with either 
PRL alone or in combination with AG490 inhibitor. a Induction of pS727‑STAT3. b Induction of antiapoptotic genes bcl‑xl, bcl‑2, survivin and Mcl‑1. c 
Apoptosis in HeLa cells after stimuli with Etoposide, PRL and AG490
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in vitro on different cell lines derived from cervical can-
cer [32].
On the other hand, a strong positive correlation of con-
stitutively active STAT3 with induction of HPV16 E6 and 
E7 oncoproteins and a negative association with levels of 
p53 and pRB on HPV16-positive cervical cancer cell lines 
(SiHa and CaSki) and primary tumor tissues, have been 
reported [33].
Furthermore, another previous work reported an over-
activation of STAT3 observed in tissues from patients 
with cervical cancer, which is associated with increased 
induction of anti-apoptotic genes such as Bcl-xl, survivin 
and Mcl-I [13].
Our results further demonstrate that PRL increases 
the induction of Bcl-xl, Bcl-2, survivin and Mcl-1 antia-
poptotic genes. Due to activation of STAT3 and the over-
induction of antiapoptotic genes found on cervical cancer 
cell lines after PRL stimulation, we decided to inhibit 
the STAT3 activation using the inhibitor AG490; which 
resulted in an impaired induction of Bcl-xl, Bcl-2, sur-
vivin and Mcl-1. In order to confirm the functional effect 
of STAT3 activation on apoptosis of cervical cancer cell 
lines, TUNEL assays were carried out and we observed 
that there is a direct correlation between the induction of 
antiapoptotic genes and apoptosis.
Similar to this finding, the suppression of STAT3 
induction or activation on SiHa and Caski was associated 
with the gradual loss of HPV16 E6 and E7 induction and 
was accompanied by the loss of cell viability [33].
Conclusion
Our findings suggest that PRL could be modulating the 
induction of antiapoptotic genes through STAT3 acti-
vation in cervical cancer cells, without discarding the 
involvement of other alternate routes to those discussed 
in this paper.
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